The Cost Effectiveness of BG-12 (Dimethyl Fumarate) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
Nov 1, 2013, 00:00 AM
10.1016/j.jval.2013.08.1826
https://www.valueinhealthjournal.com/article/S1098-3015(13)03731-5/fulltext
Section Title :
Disease-Specific Studies
Section Order :
1669
First Page :
A623
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)03731-5&doi=10.1016/j.jval.2013.08.1826